We identified p38 inhibitors as possible therapeutic agents for Friedreich ataxia through the study of a synthetic shRNA clone that rescues the growth phenotype of FRDA fibroblasts8 and reverses hallmarks of cellular senescence, including cell-cycle distribution and cytokine secretion. Here, MAPK14 is linked to Friedreich ataxia.